🌿Gracias @GrupoTTD & @RamonSalazarS x contar con Oncología @HUCA_Asturias en ensayo CR-SEQUENCE/TTD y x la oportunidad de presentar en #ESMO26 sus relevantes resultados sb el impacto en supervivencia d resección d metástasis hepáticas en CCR IV 🩺
27 views · 2 likes · 2 reposts · 0 replies
Phase 1 first-in-human (FIH) results of YL211, a c-Met targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors
https://esmocongress.esmo.orgClinical and genomic landscape of de novo MET amplified NSCLC (LC-SCRUM-Asia)
https://esmocongress.esmo.orgMCLA-129 in patients (pts) with EGFR-mutant advanced non-small cell lung cancer (NSCLC) with MET overexpression and/or amplification: Results from a phase II study
https://esmocongress.esmo.orgPhase 2 study of SHR-1826, a c-MET directed antibody-drug-conjugate, combined with PD-L1 inhibitor and CTLA-4 inhibitor in previously treated advanced/metastatic non-squamous NSCLC
https://esmocongress.esmo.org- **标题 / Title：** A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy
https://esmocongress.esmo.orgLa Dra. @PaulaJFonseca, del @HUCA_Asturias, y el Dr. Salazar, del @ICO_oncologia, han presentado los resultados del análisis multivariado de la resección de metástasis hepática, del estudio TTD-18-01 CR-SEQUENCE, del @GrupoTTD #TitularesTTD #ESMO26 https://grupottd.org/resultados-del-estudio-cr-sequence-del-ttd-presentados-en-esmo-2026/在 X 查看被引用的帖子
Source: Paula Jimenez Fonseca · x.com